{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:13:58Z","timestamp":1790712838727,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["PARSEK17IO"],"award-info":[{"award-number":["PARSEK17IO"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["WATERS19AO-1"],"award-info":[{"award-number":["WATERS19AO-1"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009056","name":"Canadian Glycomics Network","doi-asserted-by":"publisher","award":["ID-03"],"award-info":[{"award-number":["ID-03"]}],"id":[{"id":"10.13039\/501100009056","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We previously demonstrated that\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    isolates that persisted in children with cystic fibrosis (CF) despite inhaled tobramycin treatment had increased anti-Psl antibody binding in vitro compared to those successfully eradicated. We aimed to validate these findings by directly visualizing\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    in CF sputum. This was a prospective observational study of children with CF with new-onset\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    infection who underwent inhaled tobramycin eradication treatment. Using microbial identification passive clarity technique (MiPACT),\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    was visualized in sputum samples obtained before treatment and classified as persistent or eradicated based on outcomes. Pre-treatment isolates were also grown as biofilms in vitro. Of 11 patients enrolled, 4 developed persistent infection and 7 eradicated infection.\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    biovolume and the number as well as size of\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    aggregates were greater in the sputum of those with persistent compared with eradicated infections (p\u2009&lt;\u20090.01). The amount of Psl antibody binding in sputum was also greater overall (p\u2009&lt;\u20090.05) in samples with increased\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    biovolume. When visualized in sputum,\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    had a greater biovolume, with more expressed Psl, and formed more numerous, larger aggregates in CF children who failed eradication therapy compared to those who successfully cleared their infection.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-25889-6","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:03:32Z","timestamp":1670821412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pseudomonas aeruginosa aggregation and Psl expression in sputum is associated with antibiotic eradication failure in children with cystic fibrosis"],"prefix":"10.1038","volume":"12","author":[{"given":"Amanda J.","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne C. W.","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafinaz","family":"Eisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Parsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Lynne","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas R.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"DiGiandomenico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Coburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Grana-Miraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Guttman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie J.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"key":"25889_CR1","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","volume":"397","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg, M., Haq, I. J., Polineni, D. & Davies, J. C. Cystic fibrosis. Lancet 397, 2195\u20132211. https:\/\/doi.org\/10.1016\/S0140-6736(20)32542-3 (2021).","journal-title":"Lancet"},{"key":"25889_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/ppul.1950190103","volume":"19","author":"A Pamukcu","year":"1995","unstructured":"Pamukcu, A., Bush, A. & Buchdahl, R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr. Pulmonol. 19, 10\u201315 (1995).","journal-title":"Pediatr. Pulmonol."},{"key":"25889_CR3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/ppul.23715","volume":"52","author":"SA McColley","year":"2017","unstructured":"McColley, S. A. et al. Risk factors for mortality before age 18 years in cystic fibrosis. Pediatr. Pulmonol. 52, 909\u2013915. https:\/\/doi.org\/10.1002\/ppul.23715 (2017).","journal-title":"Pediatr. Pulmonol."},{"key":"25889_CR4","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","volume":"11","author":"PJ Mogayzel Jr","year":"2014","unstructured":"Mogayzel, P. J. Jr. et al. Cystic Fibrosis Foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann. Am. Thorac. Soc. 11, 1640\u20131650. https:\/\/doi.org\/10.1513\/AnnalsATS.201404-166OC (2014).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"25889_CR5","doi-asserted-by":"crossref","unstructured":"Gascon Casaredi, I. S. M., Waters, V., Seeto, R., Blanchard, A., Ratjen, F. Impact of antibiotic eradication therapy of Pseudomonas aeruginosa on long term lung function in cystic fibrosis. J. Cystic Fibros. (2022) (in press).","DOI":"10.1016\/j.jcf.2022.08.007"},{"key":"25889_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41522-021-00234-3","volume":"7","author":"AJ Morris","year":"2021","unstructured":"Morris, A. J. et al. The role of Psl in the failure to eradicate Pseudomonas aeruginosa biofilms in children with cystic fibrosis. NPJ Biofilms Microbiomes 7, 63. https:\/\/doi.org\/10.1038\/s41522-021-00234-3 (2021).","journal-title":"NPJ Biofilms Microbiomes"},{"key":"25889_CR7","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1128\/JB.186.14.4466-4475.2004","volume":"186","author":"KD Jackson","year":"2004","unstructured":"Jackson, K. D., Starkey, M., Kremer, S., Parsek, M. R. & Wozniak, D. J. Identification of psl, a locus encoding a potential exopolysaccharide that is essential for Pseudomonas aeruginosa PAO1 biofilm formation. J. Bacteriol. 186, 4466\u20134475. https:\/\/doi.org\/10.1128\/JB.186.14.4466-4475.2004 (2004).","journal-title":"J. Bacteriol."},{"key":"25889_CR8","doi-asserted-by":"publisher","first-page":"8353","DOI":"10.1128\/JB.00620-07","volume":"189","author":"L Ma","year":"2007","unstructured":"Ma, L., Lu, H., Sprinkle, A., Parsek, M. R. & Wozniak, D. J. Pseudomonas aeruginosa Psl is a galactose- and mannose-rich exopolysaccharide. J. Bacteriol. 189, 8353\u20138356. https:\/\/doi.org\/10.1128\/JB.00620-07 (2007).","journal-title":"J. Bacteriol."},{"key":"25889_CR9","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1365-2958.2009.06795.x","volume":"73","author":"MS Byrd","year":"2009","unstructured":"Byrd, M. S. et al. Genetic and biochemical analyses of the Pseudomonas aeruginosa Psl exopolysaccharide reveal overlapping roles for polysaccharide synthesis enzymes in Psl and LPS production. Mol. Microbiol. 73, 622\u2013638. https:\/\/doi.org\/10.1111\/j.1365-2958.2009.06795.x (2009).","journal-title":"Mol. Microbiol."},{"key":"25889_CR10","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1111\/j.1462-2920.2011.02503.x","volume":"13","author":"L Yang","year":"2011","unstructured":"Yang, L. et al. Distinct roles of extracellular polymeric substances in Pseudomonas aeruginosa biofilm development. Environ. Microbiol. 13, 1705\u20131717. https:\/\/doi.org\/10.1111\/j.1462-2920.2011.02503.x (2011).","journal-title":"Environ. Microbiol."},{"key":"25889_CR11","doi-asserted-by":"publisher","first-page":"e01536","DOI":"10.1128\/mBio.01536-14","volume":"5","author":"SC Chew","year":"2014","unstructured":"Chew, S. C. et al. Dynamic remodeling of microbial biofilms by functionally distinct exopolysaccharides. MBio 5, e01536-e11514. https:\/\/doi.org\/10.1128\/mBio.01536-14 (2014).","journal-title":"MBio"},{"key":"25889_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000354","volume":"5","author":"L Ma","year":"2009","unstructured":"Ma, L. et al. Assembly and development of the Pseudomonas aeruginosa biofilm matrix. PLoS Pathog. 5, e1000354. https:\/\/doi.org\/10.1371\/journal.ppat.1000354 (2009).","journal-title":"PLoS Pathog."},{"key":"25889_CR13","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1093\/cid\/ciz364","volume":"69","author":"VJ Waters","year":"2019","unstructured":"Waters, V. J. et al. Reconciling antimicrobial susceptibility testing and clinical response in antimicrobial treatment of chronic cystic fibrosis lung infections. Clin. Infect. Dis. 69, 1812\u20131816. https:\/\/doi.org\/10.1093\/cid\/ciz364 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"25889_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.01.008","author":"R Somayaji","year":"2019","unstructured":"Somayaji, R. et al. Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. J. Cystic Fibros. https:\/\/doi.org\/10.1016\/j.jcf.2019.01.008 (2019).","journal-title":"J. Cystic Fibros."},{"key":"25889_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00796-16","author":"WH DePas","year":"2016","unstructured":"DePas, W. H. et al. Exposing the three-dimensional biogeography and metabolic states of pathogens in cystic fibrosis sputum via hydrogel embedding, clearing, and rRNA labeling. MBio https:\/\/doi.org\/10.1128\/mBio.00796-16 (2016).","journal-title":"MBio"},{"key":"25889_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10096-015-2509-4","volume":"35","author":"P Vidya","year":"2016","unstructured":"Vidya, P. et al. Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis. Eur. J. Clin. Microbiol. Infect. Dis. 35, 67\u201374. https:\/\/doi.org\/10.1007\/s10096-015-2509-4 (2016).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"25889_CR17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/cid\/ciu385","volume":"59","author":"N Mayer-Hamblett","year":"2014","unstructured":"Mayer-Hamblett, N. et al. Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis. Clin. Infect. Dis. 59, 624\u2013631. https:\/\/doi.org\/10.1093\/cid\/ciu385 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"25889_CR18","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.tim.2013.06.002","volume":"21","author":"T Bjarnsholt","year":"2013","unstructured":"Bjarnsholt, T. et al. The in vivo biofilm. Trends Microbiol. 21, 466\u2013474. https:\/\/doi.org\/10.1016\/j.tim.2013.06.002 (2013).","journal-title":"Trends Microbiol."},{"key":"25889_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108782","volume":"34","author":"LK Jennings","year":"2021","unstructured":"Jennings, L. K. et al. Pseudomonas aeruginosa aggregates in cystic fibrosis sputum produce exopolysaccharides that likely impede current therapies. Cell Rep. 34, 108782. https:\/\/doi.org\/10.1016\/j.celrep.2021.108782 (2021).","journal-title":"Cell Rep."},{"key":"25889_CR20","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1164\/rccm.201312-2142OC","volume":"189","author":"BJ Staudinger","year":"2014","unstructured":"Staudinger, B. J. et al. Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 189, 812\u2013824. https:\/\/doi.org\/10.1164\/rccm.201312-2142OC (2014).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"25889_CR21","doi-asserted-by":"publisher","first-page":"10780","DOI":"10.1073\/pnas.1806005115","volume":"115","author":"PR Secor","year":"2018","unstructured":"Secor, P. R., Michaels, L. A., Ratjen, A., Jennings, L. K. & Singh, P. K. Entropically driven aggregation of bacteria by host polymers promotes antibiotic tolerance in Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 115, 10780\u201310785. https:\/\/doi.org\/10.1073\/pnas.1806005115 (2018).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"25889_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1365-2958.2005.04941.x","volume":"59","author":"RM Landry","year":"2006","unstructured":"Landry, R. M., An, D., Hupp, J. T., Singh, P. K. & Parsek, M. R. Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance. Mol. Microbiol. 59, 142\u2013151. https:\/\/doi.org\/10.1111\/j.1365-2958.2005.04941.x (2006).","journal-title":"Mol. Microbiol."},{"issue":"12","key":"25889_CR23","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/s41564-019-0536-0","volume":"4","author":"AJ Lopatkin","year":"2020","unstructured":"Lopatkin, A. J. et al. Bacterial metabolic state more accurately predicts antibiotic lethality than growth rate. Nat. Microbiol. 4(12), 2109\u20132117. https:\/\/doi.org\/10.1038\/s41564-019-0536-0 (2019).","journal-title":"Nat. Microbiol."},{"key":"25889_CR24","doi-asserted-by":"publisher","DOI":"10.3791\/61631","author":"L Jackson","year":"2020","unstructured":"Jackson, L. et al. Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients. J. Vis. Exp. JoVE https:\/\/doi.org\/10.3791\/61631 (2020).","journal-title":"J. Vis. Exp. JoVE"},{"key":"25889_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-217576","author":"M Kolpen","year":"2022","unstructured":"Kolpen, M. et al. Bacterial biofilms predominate in both acute and chronic human lung infections. Thorax https:\/\/doi.org\/10.1136\/thoraxjnl-2021-217576 (2022).","journal-title":"Thorax"},{"key":"25889_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41522-017-0035-0","volume":"3","author":"T Beaudoin","year":"2017","unstructured":"Beaudoin, T. et al. Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance. NPJ Biofilms Microbiomes 3, 25. https:\/\/doi.org\/10.1038\/s41522-017-0035-0 (2017).","journal-title":"NPJ Biofilms Microbiomes"},{"key":"25889_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01763-21","volume":"12","author":"GA O\u2019Toole","year":"2021","unstructured":"O\u2019Toole, G. A. et al. Model systems to study the chronic, polymicrobial infections in cystic fibrosis: Current approaches and exploring future directions. MBio 12, e0176321. https:\/\/doi.org\/10.1128\/mBio.01763-21 (2021).","journal-title":"MBio"},{"key":"25889_CR28","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jcf.2021.06.008","volume":"20","author":"V Waters","year":"2021","unstructured":"Waters, V. Beneath the surface: Assessing cystic fibrosis pulmonary infections in the era of highly effective modulator therapy. J. Cyst. Fibros. 20, 723\u2013724. https:\/\/doi.org\/10.1016\/j.jcf.2021.06.008 (2021).","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"25889_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.02.008","volume":"89","author":"M Rybtke","year":"2020","unstructured":"Rybtke, M., Jensen, P. O., Nielsen, C. H. & Tolker-Nielsen, T. The Extracellular Polysaccharide Matrix of Pseudomonas aeruginosa Biofilms Is a Determinant of Polymorphonuclear Leukocyte Responses. Infect. Immun. 89(1), e00631-20. https:\/\/doi.org\/10.1128\/IAI.00631-20 (2020).","journal-title":"Infect. Immun."},{"key":"25889_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.02.008","author":"AC Blanchard","year":"2018","unstructured":"Blanchard, A. C. et al. Early detection using qPCR of Pseudomonas aeruginosa infection in children with cystic fibrosis undergoing eradication treatment. J. Cyst. Fibros. https:\/\/doi.org\/10.1016\/j.jcf.2018.02.008 (2018).","journal-title":"J. Cyst. Fibros."},{"key":"25889_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jcf.2017.01.007","volume":"16","author":"AC Blanchard","year":"2017","unstructured":"Blanchard, A. C. et al. Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. J. Cyst. Fibros. 16, 395\u2013400. https:\/\/doi.org\/10.1016\/j.jcf.2017.01.007 (2017).","journal-title":"J. Cyst. Fibros."},{"key":"25889_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","volume":"2","author":"TW Lee","year":"2003","unstructured":"Lee, T. W., Brownlee, K. G., Conway, S. P., Denton, M. & Littlewood, J. M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J. Cyst. Fibros. 2, 29\u201334 (2003).","journal-title":"J. Cyst. Fibros."},{"key":"25889_CR33","doi-asserted-by":"publisher","DOI":"10.3791\/61759","author":"AJ Morris","year":"2020","unstructured":"Morris, A. J., Li, A., Jackson, L., Yau, Y. C. W. & Waters, V. Quantifying the effects of antimicrobials on in vitro biofilm architecture using COMSTAT software. JoVE. https:\/\/doi.org\/10.3791\/61759 (2020).","journal-title":"JoVE."},{"key":"25889_CR34","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1128\/AAC.02068-15","volume":"60","author":"S Kennedy","year":"2016","unstructured":"Kennedy, S. et al. Activity of tobramycin against cystic fibrosis isolates of Burkholderia cepacia complex grown as biofilms. Antimicrob. Agents Chemother. 60, 348\u2013355. https:\/\/doi.org\/10.1128\/AAC.02068-15 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"25889_CR35","doi-asserted-by":"publisher","first-page":"14728","DOI":"10.1038\/s41598-018-33016-7","volume":"8","author":"T Beaudoin","year":"2018","unstructured":"Beaudoin, T. et al. Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms. Sci. Rep. 8, 14728. https:\/\/doi.org\/10.1038\/s41598-018-33016-7 (2018).","journal-title":"Sci. Rep."},{"key":"25889_CR36","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1084\/jem.20120033","volume":"209","author":"A DiGiandomenico","year":"2012","unstructured":"DiGiandomenico, A. et al. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J. Exp. Med. 209, 1273\u20131287. https:\/\/doi.org\/10.1084\/jem.20120033 (2012).","journal-title":"J. Exp. Med."},{"key":"25889_CR37","doi-asserted-by":"publisher","DOI":"10.1101\/453142","author":"S Harris","year":"2018","unstructured":"Harris, S. SKA: Split Kmer analysis toolkit for bacterial genomic epidemiology. bioRxiv https:\/\/doi.org\/10.1101\/453142 (2018).","journal-title":"bioRxiv"},{"key":"25889_CR38","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120. https:\/\/doi.org\/10.1093\/bioinformatics\/btu170 (2014).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25889-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25889-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25889-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T17:07:15Z","timestamp":1671124035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25889-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["25889"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-25889-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,12]]},"assertion":[{"value":"4 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21444"}}